(Q36138483)

12 August 2017

1 reference

title

Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy (English)

1 reference

12 August 2017

Manfred Kaufmann

1

1 reference

PubMed ID

15915367

12 August 2017

Achim Rody

series ordinal

2

1 reference

12 August 2017

25 May 2005

1 reference

Journal of Cancer Research and Clinical Oncology

12 August 2017

1 reference

12 August 2017

131

1 reference

12 August 2017

8

1 reference

12 August 2017

487-494

1 reference

https://scigraph.springernature.com/pub.10.1007/s00432-005-0668-x

12 August 2017

0 references

cites work

Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study

1 reference

12 December 2020

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

1 reference

12 December 2020

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

12 December 2020

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.

1 reference

12 December 2020

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

1 reference

12 December 2020

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

12 December 2020

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

12 December 2020

Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies

1 reference

12 December 2020

Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study

1 reference

12 December 2020

Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.

1 reference

12 December 2020

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group

1 reference

12 December 2020

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety upda

1 reference

12 December 2020

Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer

1 reference

12 December 2020

Aromatase inhibitors in early breast cancer treatment

1 reference

12 December 2020

Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women

1 reference

12 December 2020

American Society of Clinical Oncology Technology Assessment Working Group Update: Use of Aromatase Inhibitors in the Adjuvant Setting

1 reference

12 December 2020

Antiaromatase agents: preclinical data and neoadjuvant therapy.

1 reference

12 December 2020

Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer

1 reference

12 December 2020

Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer

1 reference

12 December 2020

Use of aromatase inhibitors in breast carcinoma

1 reference

12 December 2020

Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian

1 reference

12 December 2020

An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole

1 reference

12 December 2020

Estrogen and the risk of breast cancer

1 reference

12 December 2020

Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells

1 reference

12 December 2020

Preliminary data from ongoing adjuvant aromatase inhibitor trials.

1 reference

12 December 2020

Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer

1 reference

12 December 2020

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

1 reference

12 December 2020

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors

1 reference

12 December 2020

Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors

1 reference

12 December 2020

Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial

1 reference

12 December 2020

Annual hazard rates of recurrence for breast cancer after primary therapy.

1 reference

12 December 2020

Examining quality of life issues in relation to endocrine therapy for breast cancer

1 reference

12 December 2020

Long-term exposure to tamoxifen induces hypersensitivity to estradiol

1 reference

12 December 2020

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

12 December 2020

10.1007/S00432-005-0668-X

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

15915367